A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence

Authors

Jasmine Crane
Ginger Brown
Intawat Nookaew (ORCID: https://orcid.org/0000-0001-8901-1088)
David W. Ussery (ORCID: https://orcid.org/0000-0003-3632-5512)
Oxana P. Lazarenko
Alongkorn Kurilung (ORCID: https://orcid.org/0000-0003-0839-4967)
Jennifer L. Faulkner (ORCID: https://orcid.org/0000-0001-9726-8916)
Nadia Darwish
Teresa Evans
Jumin Sunde (ORCID: https://orcid.org/0000-0002-6397-0958)
Omar Atiq (ORCID: https://orcid.org/0000-0002-7528-1367)
Rangaswamy Govindarajan
Keanna Marsh
M Moreno
Emily Ward Bivens
Emre Duval
Milan Bilami
Michael Robeson
Yong-Chen William Lu
Mayumi Nakagawa
Mindy Wilman
Aaron Johnson

Institutions

Winthrop Rockefeller Foundation (US)
University of Arkansas for Medical Sciences (US)

Publication Details

Journal: medRxiv
Published: 2026-01-12
DOI: https://doi.org/10.64898/2026.01.09.26343801
Primary Topic: Head and Neck Cancer Studies
Type: article
Field-Weighted Citation Impact: 0.00

Funders

National Institutes of Health

A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence

Jasmine Crane, Ginger Brown, Intawat Nookaew, David W. Ussery, Oxana P. Lazarenko, Alongkorn Kurilung, Jennifer L. Faulkner, Nadia Darwish, Teresa Evans, Jumin Sunde, Omar Atiq, Rangaswamy Govindarajan, Keanna Marsh, M Moreno, Emily Ward Bivens, Emre Duval, Milan Bilami, Michael Robeson, Yong-Chen William Lu, Mayumi Nakagawa, Mindy Wilman, Aaron Johnson

January 12, 2026article en

A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence

Authors

Institutions

Publication Details

Funders

A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence

A Randomized Double-Blind Placebo-Controlled Phase I/II Clinical Trial of a Human Papillomavirus Therapeutic Vaccine, PepCan, for Reducing Head and Neck Cancer Recurrence

Abstract

Ask Laika to Summarize, Analyze, and Connect papers live on the map.